1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66E096A86C69F3669002586F50037BD54
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-2025-moving-next-level-by-redefining-strategic-roles-capabilities?opendocument
18
19opendocument
203.231.230.177
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB
Access. Intelligence. Excellence

| Advanced Search | 0
Research and Consulting Areas of Expertise

Benchmarking Reports Areas of Expertise Report Catalog FAQ
Best Practice Database Areas of Expertise New Research Benefits Types Of Research Current Members
Research and Advisory Services Areas of Expertise Digital Technology Consortium Medical Affairs Consortium White Papers Research Partners Partnership Benefits Contact Us
Excellence Services Pharma and Medical Device Quality New Product Planning Medical Affairs Pharmaceutical Launch Market Research Competitive Intelligence

Industries

Biotechnology Financial Services Healthcare Medical Device Manufacturing Pharmaceuticals Technology and Communications

Functions

Brand Management & Product Leadership Competitive & Business Intelligence Customer Service Clinical Operations Human Resources Medical Affairs Managed Care Market Research, Analytics & Forecasting

 

Marketing Management Patient Access, Support, Insights and Operations Product Launch Pull Through Pharma Launch Playbook Scenario Planning / War Gaming Sales Supply Chain
Corporate Overview About Benchmarking Benchmarking Books What is a Best Practice? Research Methodology

Our Clients Testimonials

Our Team Careers Best Practices Interns Work at Best Practices, LLC Help Set Research Agenda Blog
Follow Best Practices LLC linkedIn twitter slideshare youtube pinterest

Overview Press Releases Speaking Events Media Coverage Receive Research Updates Contact Us
Address/Email/Phone Schedule a Meeting
Report Catalog Blog
Database Member Home RAS Member Home

» Products & Services » » Medical Affairs » Medical Affairs Excellence

Medical Affairs 2025: Moving to the Next Level by Redefining Strategic Roles and Capabilities

DB Image

Download FREE Excerpt

ID: 5678

Features:

4 Info Graphics

18 Data Graphics

380+ Metrics

Pages/Slides: 30

Published: 2021

Delivery Format: Online PDF Document

 

License Options:


Buy Now

 

919-403-0251
Schedule a Meeting
Request a Quote


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical Affairs 2025: Moving to the Next Level by Redefining Strategic Roles and Capabilities”

STUDY OVERVIEW

The Medical Affairs function has significantly evolved over the last few years from a support function to what many view as the third leadership pillar in biopharma. Moreover, the global COVID-19 pandemic has triggered a tsunami of rapid role changes for Medical Affairs in particular.

While many of the underlying trends will continue, the Medical Affairs function will also see new stakeholder priorities and growth levels as we approach 2025.

Best Practices, LLC undertook this research to explore a four-year future horizon for Medical Affairs. This research probes evolving stakeholder priorities, roles, and capabilities. It further explores the direction and velocity of change.

KEY TOPICS

  • Medical Affairs Priorities for 2025
  • Medical Affairs’ Leadership and Strategic Roles
  • Medical’s Capabilities and Stakeholder Involvement

KEY METRICS
  • What is the current and future state of Medical Affairs’ strategic role in the listed areas?
  • How important are the listed elements to the foundational Medical Affairs capabilities?
  • Which of the listed external stakeholder groups does/will Medical Affairs work with?
  • How important and effective are the listed external groups to the work conducted within your Medical Affairs organization?

SAMPLE KEY FINDINGS
  • Stakeholder Involvement: HCPs, Thought Leaders and Guideline Orgs. will remain key stakeholders. Payers, Advocacy Groups, Govt. Agencies, ACO/ IDNs, Pathway Vendors, Large employer groups & specialty pharmacies are high-growth areas headed towards 2025.

METHODOLOGY

Best Practices, LLC developed a benchmark protocol that examines current and future medical operations, capabilities, and performance. The research analysis engaged 74 executives from 57 leading life sciences companies. Chief Medical Officers and Medical Directors represent nearly 80% of the leaders who reflected on current medical trends and future directions in this study.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Medical Device; Diagnostic; Health Care; Medical; Consulting; Consumer Products; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; Alkermes; Apellis Pharmaceuticals; ASC Therapeutics; Astellas; AstraZeneca; Aziyo Biologics; Inc.; Baxter Healthcare; BioMarin; bioMerieux; Boehringer Ingelheim; Castle Creek Biosciences; Cipla; Clovis Oncology; Eisai; Eli Lilly; EMD Serono; Gama PharMed Solutions Limited; Glenmark; Gossamer Bio; Greenwich Biosciences; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson; Leica Biosystems; LEO Pharma; Lundbeck; Maxwell Clinic; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck; Milestone Pharmaceuticals; Natera; NexGen Pharma; Novartis; Novavax; Novo Nordisk; Orion Pharmaceuticals; Pfizer; Partner Therapeutics (PTx); Regeneron; Roche; Sandoz; Sanofi; Sanofi Genzyme; Santen; Servier; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; United Therapeutics; Virbac; Zoetis Inc.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

RELATED RESEARCH